Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

ImmunoMet starts Phase I of IM156 for solid tumors

Elizabeth S. Eaton
November 3, 2017 4:50 AM UTC

ImmunoMet Therapeutics Inc. (Houston, Texas) began a Phase I trial of IM156 to treat solid tumors in up to 36 patients. The primary endpoint is to determine the maximum tolerated dose (MTD) and recommended Phase II dose. Secondary endpoints include preliminary tumor response and pharmacokinetics.

IM156 is a biguanide derivative that inhibits mitochondrial oxidative phosphorylation complex I (OXPHOS complex I)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Hanall Biopharma Co. Ltd.

Immunomet Therapeutics Inc.